Taken together these data indicate that selective BCL-2 blockade enhances the in vitro activity of CHK inhibitors in multiple BCL-2 positive DLBCL models including HG-BCL w/DH, by inducing oxidative DNA damage and apoptosis. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.